The Mass Spectrometry Core will provide the powerful tools of modern mass spectrometry to DPPG investigators. Quantification of both lipids and oxidized amino acids by GC/MS remains a mainstay of the Core. The Core will also permit structural identification and quantitation of high density lipoprotein (HDL)- related biomolecules, including apolipoprotein A-l and serum amyloid protein. Over the past two years, Core personnel have also become proficient in 2-dimensional liquid chromatography-electrospray ionization- MS/MS analysis (shotgun proteomics) of complex biological mixtures of proteins, and we anticipate that all investigators will take advantage of this capability in the next funding period. In addition to providing instrumental capabilities, Mass Spectrometry Core staff will provide consultation and collaboration on the application of mass spectrometry to the DPPG research program, and this will include development of new analytical methods targeted at achieving research objectives of DPPG investigators. The Mass Spectrometry Core will optimize the efficiency and cost-effectiveness through which these services are provided to DPPG investigators by providing a central laboratory. This avoids the need for individual DPPG investigators to maintain the required instrumentation in their own laboratories and avoids the high cost of commercial mass spectrometric services. By centralizing and standardizing procedures, the Mass Spectrometry Core will provide a common set of analytical tools that will lead to a unified understanding of molecular mechanisms involved in physiologic and pathophysiologic processes of diabetic vascular disease.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-PPG-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Krishack, Paulette A; Sontag, Timothy J; Getz, Godfrey S et al. (2016) Serum amyloid A regulates monopoiesis in hyperlipidemic Ldlr(-/-) mice. FEBS Lett 590:2650-60
Ronsein, Graziella E; Hutchins, Patrick M; Isquith, Daniel et al. (2016) Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects. Arterioscler Thromb Vasc Biol 36:404-11
Shimizu-Albergine, Masami; Van Yserloo, Brian; Golkowski, Martin G et al. (2016) SCAP/SREBP pathway is required for the full steroidogenic response to cyclic AMP. Proc Natl Acad Sci U S A 113:E5685-93
Bornfeldt, Karin E (2016) Does Elevated Glucose Promote Atherosclerosis? Pros and Cons. Circ Res 119:190-3
Han, Chang Yeop (2016) Roles of Reactive Oxygen Species on Insulin Resistance in Adipose Tissue. Diabetes Metab J 40:272-9
Monette, Jeffrey S; Hutchins, Patrick M; Ronsein, Graziella E et al. (2016) Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration. Circ Res 119:83-90
Ronsein, Graziella E; Reyes-Soffer, Gissette; He, Yi et al. (2016) Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone. Mol Cell Proteomics 15:1083-93
Han, Chang Yeop; Tang, Chongren; Guevara, Myriam E et al. (2016) Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest 126:266-81
Tang, Chongren; Liu, Yuhua; Yang, Wendy et al. (2016) Hematopoietic ABCA1 deletion promotes monocytosis and worsens diet-induced insulin resistance in mice. J Lipid Res 57:100-8
Schulze, P Christian; Drosatos, Konstantinos; Goldberg, Ira J (2016) Lipid Use and Misuse by the Heart. Circ Res 118:1736-51

Showing the most recent 10 out of 95 publications